SCHEMBL15713924

SCHEMBL15713924

O=C(c1ccc(NS(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)N1CC(O)(Cc2ccccc2)C1

nearest known ligand 0.84

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PKLR P30613 14/20 0.84
▸ HDAC3 O15379 1/20 0.54
▸ HDAC4 P56524 1/20 0.54
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC7 Q8WUI4 1/20 0.54
▸ HDAC2 Q92769 1/20 0.54
▸ HDAC10 Q969S8 1/20 0.54
▸ HDAC11 Q96DB2 1/20 0.54
▸ HDAC8 Q9BY41 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ HDAC9 Q9UKV0 1/20 0.54
▸ HDAC5 Q9UQL6 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.50
▸ PKM P14618 2/20 0.50
▸ LMNA P02545 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ SERPINE1 P05121 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084069 0.91 PKLR (1.00) PKLRHDAC3HDAC4HDAC1HDAC7
SCHEMBL15713345 0.90 PKLR (0.69) PKLRHDAC3HDAC4HDAC1HDAC7
SCHEMBL15713347 0.86 PKLR (0.83) PKLRALDH1A1GAASMN1; SMN2
SCHEMBL15713346 0.83 PKLR (0.82) PKLRHDAC3HDAC4HDAC1HDAC7
SCHEMBL15713609 0.82 PKLR (0.63) PKLRALDH1A1PKM
SCHEMBL15713683 0.82 PKLR (0.67) PKLRALDH1A1PKMGAASMN1; SMN2
SCHEMBL16083860 0.81 PKLR (0.82) PKLRHDAC3HDAC4HDAC1HDAC7
SCHEMBL15713606 0.78 PKLR (0.81) PKLRALDH1A1PKMGAASMN1; SMN2
SCHEMBL15713928 0.78 PKLR (0.82) PKLRALDH1A1PKM
SCHEMBL15713676 0.78 PKLR (0.84) PKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458132-B2 Therapeutic compounds and compositions and their use as PKM2 modulators AGIOS PHARMACEUTICALS, INC (US) 2016-10-04 — — US disclosed
US-20150307473-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS AGIOS PHARMACEUTICALS, INC (US) 2015-10-29 — — US disclosed
WO-2014074848-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS AGIOS PHARMACEUTICALS, INC. (US) 2014-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307473-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS PDK1, PDK2, PDK3 PKLR 12/4885HDAC3 320/4885HDAC4 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback